USA - NYSE:PEN - US70975L1070 - Common Stock
The current stock price of PEN is 253.37 USD. In the past month the price decreased by -6.74%. In the past year, price increased by 32.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.26 | 232.44B | ||
ISRG | INTUITIVE SURGICAL INC | 54.8 | 158.13B | ||
BSX | BOSTON SCIENTIFIC CORP | 34.69 | 145.48B | ||
SYK | STRYKER CORP | 28.72 | 141.08B | ||
MDT | MEDTRONIC PLC | 17.04 | 120.86B | ||
BDX | BECTON DICKINSON AND CO | 12.94 | 52.91B | ||
IDXX | IDEXX LABORATORIES INC | 52.64 | 50.58B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.67 | 44.77B | ||
RMD | RESMED INC | 28.3 | 39.57B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.55 | 33.08B | ||
DXCM | DEXCOM INC | 39.47 | 26.31B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.87 | 25.83B |
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,500 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
PENUMBRA INC
One Penumbra Place
Alameda CALIFORNIA 94502 US
CEO: Adam Elsesser
Employees: 4500
Phone: 15109952486
The current stock price of PEN is 253.37 USD. The price increased by 1.67% in the last trading session.
The exchange symbol of PENUMBRA INC is PEN and it is listed on the New York Stock Exchange, Inc. exchange.
PEN stock is listed on the New York Stock Exchange, Inc. exchange.
23 analysts have analysed PEN and the average price target is 318.84 USD. This implies a price increase of 25.84% is expected in the next year compared to the current price of 253.37. Check the PENUMBRA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PENUMBRA INC (PEN) has a market capitalization of 9.88B USD. This makes PEN a Mid Cap stock.
PENUMBRA INC (PEN) currently has 4500 employees.
PENUMBRA INC (PEN) has a support level at 242.7 and a resistance level at 254.47. Check the full technical report for a detailed analysis of PEN support and resistance levels.
The Revenue of PENUMBRA INC (PEN) is expected to grow by 14.71% in the next year. Check the estimates tab for more information on the PEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PEN does not pay a dividend.
PENUMBRA INC (PEN) will report earnings on 2025-10-28, after the market close.
The PE ratio for PENUMBRA INC (PEN) is 72.19. This is based on the reported non-GAAP earnings per share of 3.51 and the current share price of 253.37 USD. Check the full fundamental report for a full analysis of the valuation metrics for PEN.
The outstanding short interest for PENUMBRA INC (PEN) is 4.77% of its float. Check the ownership tab for more information on the PEN short interest.
ChartMill assigns a technical rating of 3 / 10 to PEN. When comparing the yearly performance of all stocks, PEN is one of the better performing stocks in the market, outperforming 76.38% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to PEN. PEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months PEN reported a non-GAAP Earnings per Share(EPS) of 3.51. The EPS increased by 41.53% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 11.54% | ||
ROA | 8.82% | ||
ROE | 11.41% | ||
Debt/Equity | 0.02 |
23 analysts have analysed PEN and the average price target is 318.84 USD. This implies a price increase of 25.84% is expected in the next year compared to the current price of 253.37.
For the next year, analysts expect an EPS growth of 31.21% and a revenue growth 14.71% for PEN